Incidence and Consequence of Nontarget Embolization Following Bland Hepatic Arterial Embolization
Overview
Authors
Affiliations
Purpose: Estimate the incidence of nontarget embolization (NTE) as identified on immediate post-hepatic artery embolization CT.
Materials And Methods: Two hundred hepatic embolizations performed with particles alone (bland embolization) in 147 patients between August 16, 2013 and August 26, 2014 with immediate post-procedure CT were retrospectively reviewed. Arterial anatomy, vessels treated, imaging findings of NTE, patient demographics, length of hospital stay following embolization, and procedure-related complications were recorded. The data were analyzed using two-sided t-tests and chi-squared tests.
Results: Evidence of NTE was seen on post-procedure CT in 64 of 200 cases (64/200, 32%). Six organs were affected, with 69 discrete sites in 64 patients. The majority (49/69, 71.0%) involved the gallbladder. The mean length of hospital stay (LOS) for patients with and without NTE was 2.9 ± 1.5 nights (range 1-7) and 2.9 ± 2.3 nights (range 0-21), respectively (P = 0.81). NTE was more common following embolization of replaced or accessory hepatic vessels. There were three complications in the NTE group (3/64, 4.7%) following the embolization procedure, one of which was cholecystitis directly related to NTE. The other two were one incidence each of contrast-induced nephropathy and pneumonia. In the group without NTE, seven complications occurred (7/136, 5.1%, P = 0.889), including one death resulting from hepatic failure, two gastrointestinal bleeds, two hepatic abscesses, flash pulmonary edema, and pancreatitis.
Conclusion: Unanticipated NTE is not uncommon after bland hepatic artery embolization, particularly after treating accessory or replaced vessels, but does not increase complications or LOS.
Level Of Evidence: Level 2b, Retrospective Cohort.
Cone Beam Computed Tomography for the Interventional Oncologist: A Practical Approach.
May B, Charalel R Semin Intervent Radiol. 2024; 41(3):252-257.
PMID: 39165650 PMC: 11333112. DOI: 10.1055/s-0044-1788006.
Ioannidis O, Malliora A, Christidis P, Pramateftakis M, Kotidis E, Mantzoros I Curr Health Sci J. 2022; 48(2):235-241.
PMID: 36320869 PMC: 9590359. DOI: 10.12865/CHSJ.48.02.15.
Yang X, Lan T, Zhong H, Zhang Z, Xie H, Li Y J Healthc Eng. 2022; 2022:8223336.
PMID: 35356619 PMC: 8959991. DOI: 10.1155/2022/8223336.
Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions.
Bajwa R, Madoff D, Kishore S Dig Dis Interv. 2020; 4(2):134-147.
PMID: 32832829 PMC: 7437993. DOI: 10.1055/s-0040-1712146.
Barat M, Cottereau A, Kedra A, Dermine S, Palmieri L, Coriat R J Clin Med. 2020; 9(7).
PMID: 32698459 PMC: 7408651. DOI: 10.3390/jcm9072302.